当前位置: X-MOL 学术World J. Clin. Cases › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Theory and reality of antivirals against SARS-CoV-2.
World Journal of Clinical Cases ( IF 1.1 ) Pub Date : 2021-8-28 , DOI: 10.12998/wjcc.v9.i23.6663
Bo Zhao 1 , Teng-Fei Yang 2 , Rui Zheng 1
Affiliation  

At present, over 180 million people have been infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) worldwide and there have been more than 3.8 million deaths due to the virus. However, specific effective antiviral treatment for this infectious disease is absent. At the beginning of the epidemic, relevant cellular and animal experiments of antiviral treatment for SARS-CoV-2 were conducted based on the prior studies of SARS-CoV and Middle East respiratory syndrome coronavirus. Some antivirals were preliminarily validated to be potentially effective in the clinical settings. But as the epidemic continued and more studies were carried out, the efficacy of these antiviral drugs became controversial. This paper reviews the pharmacology and application of interferon, lopinavir/ritonavir, ribavirin, chloroquine, arbidol, favipiravir, remdesivir, and thymosin α1 in coronavirus disease 2019. The actual effect of these drugs remains controversial. Meanwhile, the efficacy and safety of these drugs for patients with coronavirus disease 2019 still need to be explored.

中文翻译:

针对 SARS-CoV-2 的抗病毒药物的理论与现实。

目前,全球已有超过1.8亿人感染严重急性呼吸综合征冠状病毒2(SARS-CoV-2),并有超过380万人死于该病毒。然而,针对这种传染病缺乏特异性有效的抗病毒治疗。疫情初期,在前期对SARS-CoV和中东呼吸综合征冠状病毒的研究基础上,开展了针对SARS-CoV-2抗病毒治疗的相关细胞和动物实验。一些抗病毒药物经初步验证在临床环境中可能有效。但随着疫情的持续以及更多研究的开展,这些抗病毒药物的疗效引发了争议。本文综述了干扰素、洛匹那韦/利托那韦、利巴韦林、氯喹、阿比朵尔、法匹拉韦、瑞德西韦、胸腺素α1在2019冠状病毒病中的药理学和应用。这些药物的实际效果仍存在争议。同时,这些药物对2019冠状病毒病患者的疗效和安全性仍需探索。
更新日期:2021-08-28
down
wechat
bug